Four ways Pharma Can Comply with Obamacare

Four tips on how to ready your company for the ACA unknowns

By Jon Smith, Director of Industry Development at Revitas

This article originally appeared on 


One of the biggest challenges pharmaceutical manufacturers face in trying to establish compliance with the Affordable Care Act (ACA) is uncertainty. With so many details of the 906-page legislation still undefined and awaiting final guidance, determining the scope, timing, and impact of its contents has been like a high-stakes game of poker — a blend of skill, bluffing, and betting. And just like high-stakes poker, the consequences of a misstep could cost the players dearly.


Pharma companies are overwrought with questions, some pertaining to pharma’s already tenuous relationship with the public. How will consumers perceive the ’transfers of value’ made from manufacturers to physicians? Still other questions investigate a deeper unknown: penalties. How often and to what degree will the Department of Justice pursue manufacturers when they violate new facets of the ACA?


The one guiding principle when facing ACA compliance: Be prepared. Here are four tips on how to ready your company for the ACA unknowns.

Free Subscriptions

Pharma Manufacturing Digital Edition

Access the entire print issue on-line and be notified each month via e-mail when your new issue is ready for you. Subscribe Today. E-Newsletters

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.